Literature DB >> 19451290

In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.

Kazuko Yamamoto1, Katsunori Yanagihara, Kazuyuki Sugahara, Yoshifumi Imamura, Masafumi Seki, Koichi Izumikawa, Hiroshi Kakeya, Yoshihiro Yamamoto, Yoichi Hirakata, Shimeru Kamihira, Shigeru Kohno.   

Abstract

We evaluated the potency of garenoxacin in selecting resistant Streptococcus pneumoniae mutants by determining its mutant prevention concentration, using strains with and without topoisomerase gene mutations, and compared its potency to that of other quinolones. Garenoxacin had a significantly greater potency against pneumococci, including strains containing topoisomerase mutations. Genetic analysis of the S. pneumoniae mutants created by garenoxacin revealed that the gyrA gene was a primary target of garenoxacin.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19451290      PMCID： PMC2715604          DOI： 10.1128/AAC.00176-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  J Liñares; A G de la Campa; R Pallares
Journal:  N Engl J Med       Date:  1999-11-11       Impact factor: 91.245

2.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Authors:  Ross Davidson; Rodrigo Cavalcanti; James L Brunton; Darrin J Bast; Joyce C S de Azavedo; Pamela Kibsey; Christine Fleming; Donald E Low
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

4.  Rapid screening of topoisomerase gene mutations by a novel melting curve analysis method for early warning of fluoroquinolone-resistant Streptococcus pneumoniae emergence.

Authors:  Kazuko Y Fukushima; Yoichi Hirakata; Kazuyuki Sugahara; Katsunori Yanagihara; Akira Kondo; Shigeru Kohno; Shimeru Kamihira
Journal:  J Clin Microbiol       Date:  2006-10-04       Impact factor: 5.948

5.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.

Authors:  Ronald N Jones; Thomas R Fritsche; Helio S Sader; Matthew G Stilwell
Journal:  Diagn Microbiol Infect Dis       Date:  2007-04-03       Impact factor: 2.803

7.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

8.  Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

Authors:  P L Ho; R W Yung; D N Tsang; T L Que; M Ho; W H Seto; T K Ng; W C Yam; W W Ng
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

9.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

10.  Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.

Authors:  Andrea Endimiani; Gioconda Brigante; Alessia A Bettaccini; Francesco Luzzaro; Paolo Grossi; Antonio Q Toniolo
Journal:  BMC Infect Dis       Date:  2005-11-24       Impact factor: 3.090
View more
  5 in total

1.  Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Pamela McGhee; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

2.  In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions.

Authors:  Mika Murata; Kosuke Kosai; Shunsuke Yamauchi; Daisuke Sasaki; Norihito Kaku; Naoki Uno; Yoshitomo Morinaga; Hiroo Hasegawa; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Mukae; Katsunori Yanagihara
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

3.  Mutant prevention concentrations of four carbapenems against gram-negative rods.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

4.  Molecular Investigation of Quinolone Resistance of Quinolone Resistance-Determining Region in Streptococcus pneumoniae Strains Isolated from Iran Using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Method.

Authors:  Mohammad Kargar; Fataneh Moein Jahromi; Abbas Doosti; Somayeh Handali
Journal:  Osong Public Health Res Perspect       Date:  2014-09-06

5.  Resistance of M. leprae to quinolones: a question of relativity?

Authors:  Nicolas Veziris; Aurélie Chauffour; Sylvie Escolano; Sarah Henquet; Masanori Matsuoka; Vincent Jarlier; Alexandra Aubry
Journal:  PLoS Negl Trop Dis       Date:  2013-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.